Intertek Group plc: The Invisible Sovereign of Global Trade

I. Introduction & The Silent Sovereign of Global Trade [15 Minutes]

Turn over the bedside lamp in an American hotel room and you will find, moulded into the plastic base or stamped on a foil sticker, a small circular mark containing three letters: ETL. Most people have looked at that mark ten thousand times without once wondering what it means.

It means a laboratory tested the lamp, confirmed it would not electrocute the guest or set fire to the curtains, and certified it against a published safety standard. It means a retailer's buying department could put the lamp on a shelf without personally assuming liability for it. And it means that somewhere in a ledger in London, a few pence of revenue was recognised.

Multiply that by the toys in a child's bedroom, the cotton in a T-shirt, the jet fuel pumped into a wide-body at Honolulu, the solar module bolted to a rooftop in Gujarat, the inhaler manufactured in a Cambridgeshire cleanroom, and the ISO certificate hanging in the reception of a Malaysian factory, and you begin to see the shape of a company that most consumers will never knowingly encounter and most investors have never fully understood.

Intertek Group plc operates more than 1,000 laboratories and offices across more than 100 countries and serves over 400,000 clients.¹ It sells no product. It manufactures nothing. What it sells is the reduction of somebody else's risk.

That business generated £3,431.6m of revenue in the twelve months to 31 December 2025 and £619.6m of adjusted operating profit, an adjusted operating margin of 18.1%.³ Return on invested capital was 21.3%, and 23.0% excluding acquisitions made in the prior twelve months.³ Those are not the economics of an industrial services contractor. They are closer to the economics of a toll road with a very long lease.

And here is where the story turns, because the invisible company is about to become invisible in a more literal sense.

On 18 June 2026, the boards of Intertek and Isotope Bidco Limited — a vehicle to be owned 76% by EQT funds, 16% by Luxinva and 8% by Mubadala — announced a recommended final cash acquisition of the entire issued and to be issued share capital of Intertek.² Shareholders are to receive £60.00 per share in cash and to retain the 107.7 pence FY25 final dividend, a total value of £61.077 per share, valuing the equity at approximately £9.5 billion and the enterprise at approximately £10.9 billion.² Intertek published the scheme document on 15 July 2026, and the court and general meetings that will decide the matter are scheduled for 6 August 2026 — two days from now.¹ Completion is currently expected in the fourth quarter of 2026 or the first quarter of 2027.¹

So this is not a story about a company at the beginning of its arc. It is a story about a 140-year-old compounder arriving at the end of its life as a public security, and about the far more interesting question of why. A business with 21% returns on capital, 110% cash conversion, and a century of accumulated regulatory permissions does not normally leave the London market at a 62% premium to its undisturbed share price.²³ Something in the equation was not working — either in the business, or in the market's willingness to pay for it.

The core engine is worth naming precisely, because the acronym matters. The industry is conventionally called TIC: testing, inspection and certification. Intertek's own framing is ATIC, with Assurance placed deliberately in front — the argument being that the highest-value work is not the physical test at the end of the line but the design of the client's whole risk programme.¹ Whether that "A" represents genuine economic differentiation or skilful repositioning of a mature service business is one of the central questions of this episode.

The mechanics of the model are simple enough to state and surprisingly hard to replicate. A regulator, a retailer, a government customs authority or an insurer requires that something be verified by an independent third party. The client cannot verify it themselves, because the entire value of the verification lies in the verifier having no stake in the answer.

So the client pays Intertek. The fee per test is usually small; the volume is enormous; the requirement recurs every time a product is redesigned, a supplier is changed, a standard is updated, or a shipment crosses a border. Corporate anxiety, in other words, converted into an annuity.

Here is the roadmap for what follows. We start with three separate nineteenth-century businesses — a marine cargo surveyor in England, a chemist in Montreal and a lamp-testing bureau founded by Thomas Edison — and follow them through a British trading conglomerate, a private equity buyout and a 2002 flotation. We then trace the company's transformation from a laboratory operator into a global assurance network under Dr Wolfhart Hauser, and its attempted transformation again, under André Lacroix, from physical testing into software and enterprise risk.

We will benchmark the acquisitions that defined each era — Moody International, Alchemy Systems, SAI Global Assurance — against what they actually returned. We will dissect all five divisions with the real numbers, which differ materially from the impression management's narrative leaves. We will war-game the competitive position against SGS, Bureau Veritas and Eurofins, and find one uncomfortable pattern. And we will end with the bid: what a skeptical investor would have challenged, and what EQT thinks it can do that the public market would not fund.

The thread running through all of it is a single tension. Intertek is unquestionably a high-quality business. Whether it was a high-growth business — and whether the difference between those two things justified its public market valuation — is exactly what the last four months have been about.

↑ Back to Top

II. Origins & Industrial Evolution: Edison, Brett, Hersey, & the Birth of TIC (1888–2002) [15 Minutes]

In 1885, a man named Caleb Brett set himself up in the United Kingdom to offer independent testing and certification of ships' cargoes.⁴ The problem he solved was ancient and entirely commercial. A buyer in Liverpool has contracted for a hold full of grain loaded in Odessa. The seller says it is prime. The buyer suspects otherwise, and cannot inspect it until it has already crossed a continent and an ocean. Somebody neutral, standing on the quayside with a sampling spear, is worth paying — not because they add anything to the grain, but because their signature makes the transaction possible at all.

Three years later, in 1888, Milton Hersey opened a chemical testing laboratory in Montreal, pioneering the idea of the independent testing laboratory as a standalone commercial enterprise.⁴ And in 1896, Thomas Edison established the Lamp Testing Bureau of his Edison Electric Illuminating Company in America, an operation that was later renamed Electrical Testing Laboratories and eventually shortened to ETL, and which grew over the following four decades to test for General Electric and for entirely new industries such as air conditioning.⁴

It is worth pausing on the Edison detail, because it explains something structural about this industry. Edison did not create a testing bureau out of civic virtue. The early electric light business was plagued by lamps of wildly variable quality, and variable quality was an existential threat to the adoption of electricity itself. Buildings burned.

Insurers balked. A bureau that could certify a lamp as safe protected the category, not just the customer. Every serious safety-certification franchise in the world traces back to a version of that moment, which is why these businesses are so durable: they were founded as the immune system of an emerging technology, and they never left.

The three rivers ran separately for most of a century. In 1927, Chas Warnock started a steel-inspection company in Montreal, merging with Hersey's business in 1954 to create Warnock Hersey, one of Canada's largest testing and inspection entities.⁴ In Sweden, SEMKO was founded in 1925 and registered the S-Mark, becoming the government-accredited body for mandatory electrical product certification.⁴ Each of these entities accumulated the one asset that cannot be bought quickly: the formal right, granted by a government or standards body, to say that something complies.

Then came the conglomerate. Inchcape plc, a sprawling British trading group, entered the testing industry in 1973 by establishing Labtest in Hong Kong to serve the internal needs of Dodwell, a multinational it had acquired.⁴ Labtest began with three people — Raymond Kong, Alfred Yung and Thomas Chan — focused initially on textile testing, and became the first commercial consumer goods testing facility in Hong Kong before expanding to the United States in 1975 and across Asia through the 1980s.⁴ That is not a footnote.

Labtest is the origin of what is today Intertek's most profitable division, and it was born as a captive quality function for a trading house buying garments in Asia for sale in the West.

Inchcape then bought aggressively: the Caleb Brett group and government trade inspection businesses between 1984 and 1987, ETL Testing Laboratories in 1988, Warnock Hersey in 1992, SEMKO in 1994.⁴ In 1987 it organised the collection into a division called Inchcape Testing Services.⁴ What Inchcape had assembled, almost incidentally, was a portfolio of accreditations and registrations spanning automotive, aerospace, electronics and consumer goods — the permissions, not just the equipment.

In 1996, Charterhouse Development Capital backed a management buyout of Inchcape's Testing Services division and the company was renamed Intertek Testing Services, with Richard Nelson, the existing CEO, continuing in the role.⁴ The buyout price was £380m. Six years later, on 29 May 2002, Intertek listed on the London Stock Exchange at £4 per share, with a market capitalisation of £614m, joining the FTSE 250 in the Support Services sector.⁴ At listing the company had roughly 10,500 employees, around 750 laboratories and offices, and annual revenue of approximately £450m.⁴

Note the implied economics of that flotation. A business generating £450m of revenue was valued at £614m of equity — barely 1.4 times sales. Two decades later the same enterprise would be valued at nearly £11 billion on £3.4 billion of revenue.²³ Almost all of that re-rating came from the market's gradual realisation that testing was not a low-margin outsourced service but a franchise.

Which brings us to the takeaway that matters for anyone assessing disruption risk today. The barrier here is not the laboratory equipment, which anyone with capital can buy. It is that a test result is worthless unless the party demanding it recognises the laboratory. Recognition comes from accreditation bodies, national regulators, customs authorities and retailer vendor-approval lists, each of which moves slowly and none of which has any incentive to add an unproven name.

A software startup can automate the paperwork around a compliance process. It cannot vote itself onto a customs authority's approved list. That distinction — between the workflow and the permission — is the single most important thing to hold onto as we get to the AI question later.

By 2002, then, Intertek had the permissions. What it did not yet have was scale in the one market that was about to reorganise global manufacturing entirely.

↑ Back to Top

III. The Public Era & M&A Expansion: From Lab Operator to Global Assurance Network (2002–2015) [20 Minutes]

Richard Nelson had run the business for twenty years, through the Inchcape period and the buyout and the flotation, and in 2005 he retired.⁴ His successor was Dr Wolfhart Hauser, and Hauser arrived with a specific and correct read on the decade ahead.

China had joined the World Trade Organization in 2001. What followed was the fastest reorganisation of consumer manufacturing in modern history: American and European retailers moved production of toys, textiles, footwear, appliances and electronics into southern Chinese supply chains at a pace that outran their own ability to supervise it.

A buyer in Arkansas now had a thousand suppliers it had never visited, making products it would put its own name on, in factories governed by regulations it did not understand. The buyer's exposure was not commercial. It was reputational and legal, and it was uninsurable without independent verification.

That is the wave Intertek rode, and the Labtest inheritance meant it was already standing in the water. Hauser's contribution was to shift the balance of capital allocation decisively toward consumer goods testing built around Chinese export hubs, and to keep buying complementary businesses. The results showed up in the tape with unusual clarity: the share price crossed £10 for the first time in 2007, annual revenue exceeded £1 billion in 2008 with reported revenue of £1,003.5m, the company entered the FTSE 100 for the first time in 2009, and the share price crossed £20 in 2011.⁴

In 2006 the internal business units were reorganised around customers' industries into four core divisions, and in January 2011 they were renamed and rearranged again: Oil, Chemical & Agri became Commodities and absorbed Minerals; Analytical Services became Chemicals & Pharmaceuticals; Industrial Services became Industry & Assurance.⁴ This sounds like housekeeping.

It is actually the recurring signature of the company's strategy — Intertek reorganises its reporting lines every few years to align with how clients buy, which improves commercial focus and simultaneously makes long-run divisional comparison genuinely difficult for outside analysts. That is a real limitation on external diligence, and it recurs right up to the present.

Then came the first transformational bet.

In March 2011, Intertek announced the acquisition of Moody International from Investcorp, completing it that May for £450 million, taking group headcount to around 30,000.⁴⁹ Moody brought 2,500 employees across 60 countries providing technical inspection, staffing, consulting, training and management systems certification, primarily to oil, gas and other high-risk industries, and expanded Intertek's reach into Eastern Europe, South America and Africa.⁹ The purchase price is confirmed by the company; the earnings multiple paid was not disclosed in the announcement.⁹

The strategic logic was sound on its own terms. Asset integrity management — inspecting welds, pipelines, pressure vessels and offshore platforms so they do not fail — is technically demanding, relationship-driven, and tied to the operating and capital budgets of the largest companies on earth. What the logic did not price was correlation. Moody's demand was a function of oil and gas capital expenditure, and Intertek bought it in 2011, roughly three years before crude entered a collapse that ran from 2014 into 2016 and took the entire energy services complex with it.

The lesson is not that the deal was foolish. It is a lesson about the shape of the cost base. A laboratory or an inspection crew is a fixed-cost asset with variable-revenue exposure: the mass spectrometer, the accredited chemist, the lease and the calibration schedule cost the same whether ten samples arrive or a thousand. On the way up, that is glorious — incremental revenue drops through at very high margins.

On the way down, it is brutal in exactly the same proportion. Intertek learned, expensively, that "TIC" is not one business with one cycle but a portfolio of businesses with wildly different cyclicality, and that buying scale in the most capital-intensive and most cyclical corner of it concentrates rather than diversifies risk.

Hauser's final act was another large deal in a different direction: in 2015 Intertek completed four acquisitions including PSI in the United States for $330m, a provider of testing and assurance services to commercial and civil construction markets with 2,400 people across 87 locations, bringing group headcount to 41,400 by year end.⁴ Construction testing is less cyclical than oil capex but hardly acyclical, and it is a comparatively low-margin trade.

So the honest summary of the 2002–2015 period is this. Intertek grew revenue roughly sevenfold and moved from the FTSE 250 to the FTSE 100 by correctly identifying that globalised supply chains would generate an enormous, recurring need for third-party verification. But it entered 2015 with a portfolio increasingly weighted toward heavy, cyclical, capital-hungry industrial testing, precisely the part of the business with the least pricing power and the worst operating leverage in a downturn. The consumer goods franchise was carrying the group's profitability while the newer acquisitions consumed its capital.

In May 2015, after ten years, Hauser retired.⁴ His replacement had never run a testing company, a laboratory, or anything remotely scientific.

↑ Back to Top

IV. The André Lacroix Era: The "TQA" Pivot & Digital/SaaS Transformation (2015–Present) [25 Minutes]

André Lacroix's résumé reads like a deliberate provocation to a company full of chemists and engineers. Between 1996 and 2003 he was President of Burger King International, then part of Diageo. He served as chairman and chief executive of Euro Disney S.C.A. He was Group Chief Executive of Inchcape plc — the very conglomerate that had once assembled and then sold Intertek's constituent parts, by then a global automotive distributor — from 2005 to 2015.

He has also sat as senior independent non-executive director at Reckitt Benckiser Group plc.¹² Fast food, theme parks and car dealerships: three industries defined by brand management, franchise economics and relentless operational standardisation, and not one of them a science business.

That background explains almost everything about how Lacroix has run Intertek. He did not arrive to invent new testing methods. He arrived to do to a laboratory network what he had done to consumer franchises: define a brand promise, standardise the operating model, measure everything monthly, and price for value rather than cost.

The brand promise became Total Quality Assurance, and it came with a customer promise written in the cadence of a fast-moving consumer goods company: "Intertek Total Quality Assurance expertise, delivered consistently, with precision, pace and passion, enabling our customers to power ahead safely," unveiled as part of a brand reinvention in 2017.⁴ Readers of a certain disposition will find this language grating.

It is worth taking seriously anyway, because the strategic content underneath it is real: the argument that a client should not buy individual tests transactionally from whoever is cheapest, but should buy an integrated quality programme from a single provider who understands their whole value chain. That is a deliberate attempt to convert a spot market into a relationship — and relationships price better than spot markets.

The measurement apparatus is equally revealing.

Intertek has used Net Promoter Score since 2015 to track customer satisfaction, conducting an average of 6,059 NPS interviews per month in 2025, and monitors what Lacroix calls a "5x5" database of financial and non-financial indicators across the operations.³ The employee engagement index reached a high of 93 in 2025 against 91 in 2024, and voluntary permanent employee turnover improved to a six-year low of 10.1% from 11.2%.³ In a business where the product is the judgement of a scientist or an auditor, staff turnover is not an HR metric — it is a quality metric and a cost metric simultaneously.

Falling turnover in a labour-intensive service business is genuine evidence of operational grip, not just good culture-deck material.

In May 2023 Lacroix put a formal frame around it, unveiling the AAA growth strategy — Amazing ATIC Advantage — at a capital markets event for institutional investors and sell-side analysts.⁴ The targets set then, and the delivery against them, are the strongest single piece of evidence in the management credibility file. The initial medium-term margin target was 17.5% or better.

By the FY2024 results in March 2025 the company had reached 17.4%, described the target as delivered faster than expected, and raised the medium-term ambition to 18.5%+.⁶ By FY2025 the margin was 18.1%.³ Across the three years from 2023 to 2025 the group delivered average annual revenue growth of 6% at constant currency, 240 basis points of margin accretion, average EPS growth of 12%, £2.3bn of cumulative operating cash flow, average dividend growth of 17% per year, and £985m returned to shareholders.²³ Setting a target, hitting it early, raising it, and then hitting the raised one is precisely the behaviour pattern investors should look for, and it is rarer than it should be.

Now the acquisitions, which is where the Lacroix era gets genuinely contestable.

Alchemy Systems, August 2018. Intertek paid US$480m on a cash and debt free basis for an Austin, Texas business founded in 2003 that sold SaaS-based workforce training and safety software to the food industry, with around 270 people across four US and Canadian offices.⁴¹⁰ The disclosed metrics were 2018 estimated billings of US$66m and 2018 estimated adjusted billings EBITDA of US$22m, implying 7.2 times billings and roughly 22 times billings EBITDA.¹⁰ For context, Intertek was at the time acquiring physical testing businesses at high single-digit to low-teens EBITDA multiples.

This was a software price for a software asset — Intertek was explicit that the business was capital light, structurally negative in working capital, with cash conversion above 100% and 2018 billings EBITDA margins around 30%.¹⁰

The targets attached to the deal deserve careful reading, because they are the fairest way to grade it. Management guided to 20% annual billings growth, IFRS EBITDA margin above 30% by year five, IFRS EBIT margin above 25% by year five, capex below 5% of billings, EPS accretion on a billings basis from year one — and ROIC exceeding group weighted average cost of capital by year five.¹⁰ That last item is the one to sit with.

Intertek told the market, at the outset, that this acquisition would take five years merely to clear its cost of capital. That is an unusually long runway for a company that markets itself on capital discipline, and it means the deal was priced on faith in terminal growth rather than on near-term returns.

SAI Global Assurance, announced May 2021 and completed that September. Intertek paid A$855m cash and debt free, financed with new debt facilities, for a business owned by Baring Private Equity Asia expected to generate A$240m of revenue in the year to June 2021 at a 23% adjusted EBITDA margin — implying roughly 15 times EBITDA.⁴¹¹ SAI Global Assurance brought management systems certification and second-party audits for more than 60,000 customers in around 130 countries, market leadership in Australia and scale positions in the US, Canada and the UK, plus a fast-growing Chinese business and strength in food, agriculture and quick-service restaurants.¹¹ It also brought a standards distribution business offering more than 1.5 million technical standards to over 10,000 customers, which Intertek relaunched in January 2024 as Intertek Inform.⁴¹¹ The stated targets were 300 basis points or more of margin accretion over three years, EPS accretion from the first full year, and — again — ROIC/WACC crossover by year five.¹¹

Two further moves completed the shape. In July 2022 Intertek acquired Clean Energy Associates, a provider of assurance services to solar energy markets, and in August 2023 it acquired PlayerLync, a mobile workforce enablement platform, strengthening the People Assurance offering.⁴ In June 2023 it revived the Moody brand for its energy engineering business, an unusually sentimental act for a company otherwise ruthless about brand consolidation.⁴

Lacroix's own framing of the M&A discipline, on the FY2025 results call in March 2026, was notably unquantified and notably firm: the company sets no target number of deals, prefers to cultivate bilateral relationships with owners over years rather than compete in auctions, and will not "rush to make acquisition just because we want to say we've done M&As."⁸ He also disclosed that Envirolab, QTEST, Suplilab and Aerial PV all came through that relationship route rather than a competitive process.⁸ For a serial acquirer, sourcing deals bilaterally is a genuine edge — it is the difference between paying the auction-clearing price and paying a negotiated one.

The leadership around him has turned over substantially in 2026.

On 26 March 2026 Intertek announced that Laura Crespi would become Group Chief Financial Officer and an executive director effective 10 April 2026, promoted from Regional CFO for Europe, Middle East and Africa; she joined Intertek in 2023 from RELX plc, where she had spent twelve years, having qualified as a Chartered Accountant at Deloitte.¹²¹³ Colm Deasy, CFO for the preceding period and a nine-year veteran of the group, moved to an operational role as Executive Vice President Asia Pacific based in Vietnam.¹³ Steve Mogford, who joined the board as an independent non-executive director on 1 January 2025, succeeded Andrew Martin as Chairman with effect from 20 May 2026.¹³ A new CFO and a new chairman inside two months, immediately before an unsolicited take-private approach, is a coincidence of timing worth noting even if nothing in the record suggests causation.

The portfolio Lacroix built is the thing to judge, and the numbers do not distribute the way the corporate narrative implies.

↑ Back to Top

V. Segment Economics & Materiality: Dissecting the Five Engine Divisions [25 Minutes]

There is a particular kind of disclosure that tells you more about a company than any strategy slide, and Intertek buried one in its FY2025 divisional review. Consumer Products, it noted, represented 29% of group revenue in 2025 — and 48% of group operating profit.³

Hold that alongside its opposite. World of Energy was 21% of revenue and 10% of operating profit.³ Two divisions of broadly comparable size at the top line, one generating nearly five times the profit of the other. Any investor who models Intertek as a single blended business with a single blended growth rate is modelling something that does not exist.

Here is the FY2025 picture, division by division, with the economics explained rather than merely listed.

Consumer Products delivered £983.4m of revenue and £299.3m of adjusted operating profit, a 30.4% margin, up 240 basis points at actual rates on like-for-like revenue growth of 6.3%.³ The business lines are Softlines (textiles, apparel, footwear), Hardlines (toys, furniture, appliances), Electrical & Connected World, and Government & Trade Services, which certifies imports for governments in the Middle East and Africa.¹³ A thirty-percent operating margin in a service business tells you the pricing is not being set by the cost of the test.

It is being set by what the certification is worth to a retailer who cannot ship without it — and by the fact that a global brand needs one provider who can test to American, European, Chinese and Gulf standards from the same sample. The momentum continued into 2026: H1 revenue of £504.6m, profit of £148.4m, and a 29.4% margin up 110 basis points at constant currency, with Softlines delivering high-single-digit like-for-like growth on client investment in e-commerce and sustainability.¹

Industry and Infrastructure was 25% of revenue and 15% of operating profit in 2025, generating £858.1m of revenue and £95.4m of profit at an 11.1% margin — but that margin was up 170 basis points at constant currency, and profit grew 24.1%.³ It comprises Industry Services (the old Moody business, split between capital-expenditure inspection and operating-expenditure maintenance), Minerals, and Building & Construction.

The H1 2026 improvement was sharper still: margin of 11.0%, up 230 basis points year on year, with profit up 34.0% at constant currency and Minerals delivering double-digit like-for-like growth across Asia, Africa and North America.¹ This is the clearest evidence in the accounts that the fixed-cost leverage which savaged the division after 2014 works powerfully in reverse. It is also a reminder that an 11% margin business improving 200 basis points adds more incremental profit than a 30% margin business improving 100.

World of Energy is the problem child, and management has been reasonably candid about it. FY2025 revenue fell to £729.0m, down 1.3% like-for-like at constant currency and 3.7% at actual rates, with profit down 15.0% at constant currency to £63.4m and margin down 140 basis points to 8.7%.³ The division holds Caleb Brett (cargo inspection for crude and refined products), Transportation Technologies, and Clean Energy Associates.

Transportation Technologies delivered negative high-single-digit like-for-like revenue as automotive clients cut R&D spending.³ In H1 2026 the division was flat at £358.9m with profit down 16.3% at constant currency to £24.6m and margin down to 6.9%, which the company attributed to the impact of the war in the Gulf on Caleb Brett and negative operating leverage in Transportation Technologies, where like-for-like revenue fell at a double-digit rate.¹ A sub-7% margin in a division carrying a fifth of group revenue is the arithmetic reason the group's blended margin is 18% rather than 22%.

Corporate Assurance was 15% of revenue and 19% of operating profit in 2025 — £514.0m of revenue, £116.3m of profit. But note the direction: margin fell 100 basis points at actual rates to 22.6%, and profit declined 0.8%, even as like-for-like revenue grew 6.8%.³ We will return to why that matters enormously in the next section.

Health and Safety was 10% of revenue and 7% of operating profit: £347.1m of revenue, £45.2m of profit, a 13.0% margin down 60 basis points, on like-for-like revenue growth of only 2.4%.³ Food delivered double-digit growth while Chemicals & Pharma — described by Lacroix on the results call as "a really high-margin business for us" — declined, producing an adverse mix effect.³⁸ The division inflected hard in H1 2026: like-for-like revenue up 6.3%, profit up 37.8% at constant currency to £27.0m, and margin up 210 basis points to 13.9%.¹

One risk concentration inside Consumer Products deserves flagging because it does not fit the pattern of the rest. Government & Trade Services provides certification to governments in the Middle East and Africa to facilitate imports meeting acceptable quality and safety standards, and it reported only low-single-digit like-for-like growth at constant currency in H1 2026 — the slowest line in the division.¹ Intertek does not disclose GTS revenue separately.

The qualitative point is that this is concession-like business: a small number of large, renewable government contracts, in jurisdictions where the counterparty can retender, insource, or change the regime entirely. It sits inside the group's most profitable division and is invisible in the disclosure, which is exactly the combination that produces an unwelcome surprise.

Now the materiality conclusion, which is where the conventional framing needs correcting. Consumer Products and Corporate Assurance together produced 67% of group operating profit on 44% of group revenue in 2025.³ That is the compounding engine, and it is heavily weighted toward the consumer franchise specifically — Consumer Products alone is nearly half of group profit. Corporate Assurance is the second-highest-margin division, but on FY2025 evidence it was not the margin-expansion engine; it was a margin drag.

Two practical implications follow. First, Intertek's earnings are far more exposed to global consumer goods trade flows and retailer supply-chain activity than a glance at the revenue split suggests, which makes tariff policy and trade re-routing a first-order earnings issue rather than a macro talking point. Second, the three lower-margin divisions — Industry and Infrastructure, World of Energy, Health and Safety — collectively consume a large share of the group's laboratory capital while contributing a minority of profit. Which is, of course, the observation that eventually produced a strategic review.

↑ Back to Top

VI. The "Hidden Engine": SaaS, People Assurance, & Corporate Assurance Realized [15 Minutes]

Walk onto the floor of a large poultry processing plant in Arkansas and you will find, mounted near the line, a tablet. On it, a worker who may have started that week watches a short video in their own language explaining how to handle a specific piece of equipment without contaminating product or losing a finger. The completion is logged. When an auditor arrives — possibly also from Intertek — the record is there. That tablet is what Intertek bought when it bought Alchemy, and it is the physical form of the thesis that Intertek is not merely a laboratory company but a software company in disguise.

It is a genuinely attractive thesis. It is also, on the evidence Intertek actually publishes, substantially unproven — and an independent reader has to say so plainly.

Start with what the strategic logic gets right.

Corporate Assurance sells the industry-agnostic work: Business Assurance provides accredited third-party management systems auditing and certification, second-party supplier auditing, supply chain solutions, sustainability data verification and training, while Assuris provides scientists, engineers and regulatory specialists for scientific, regulatory, environmental, health and safety challenges.¹ The growth has been the best in the group: like-for-like revenue up 10.0% in H1 2026 and 10.8% in Q1 2026, against a group rate of 4.9% and 5.4% respectively, with medium-term guidance of high-single-digit to double-digit like-for-like growth — the only division guided above mid-single digits.¹⁵⁷ Business Assurance specifically delivered double-digit like-for-like growth in H1 2026 on client investment in supply chain resilience, ethical sourcing and sustainability assurance.¹

The switching-cost argument is also real, and it is the strongest version of the moat in this division. Once an enterprise has run its ISO certifications, its supplier audit programme and its frontline training records through one provider's system for several years, changing provider means re-baselining certificates, retraining an entire workforce on a new platform, and accepting a documentation gap in exactly the records a regulator or a plaintiff's lawyer would ask to see. The cost of switching is not the licence fee. It is the compliance risk of the transition.

Now the problems, and there are three.

First, disclosure. Intertek does not report annual recurring revenue, subscription revenue, net revenue retention, or any other software metric — not in the FY2025 results announcement and not in the H1 2026 announcement. It does not disaggregate Alchemy, PlayerLync or Intertek Inform revenue at all.

Corporate Assurance is reported as two business lines, Business Assurance and Assuris, with commentary in qualitative bands.¹³ An investor who wants to underwrite a "hybrid testing/SaaS platform" re-rating is therefore being asked to do so without a single disclosed SaaS metric. That is not a small gap; it is the entire gap.

Second, the margin trajectory runs the wrong way for the thesis. If the division were being progressively colonised by high-margin software, its margin should be climbing.

Instead it fell 100 basis points in FY2025 and rose only 30 basis points at constant currency in H1 2026, to 22.3%.¹³ Management's explanation is coherent — a mix effect from slower growth at Assuris than Business Assurance, plus deliberate investment in technology and auditor capacity — and Lacroix said directly on the results call that Intertek does not guide margin by division, while allowing that there were opportunities in 2026 for both Corporate Assurance and Health and Safety "to do better."⁸ But notice what the coherent explanation concedes.

The division's growth is currently constrained by, and its margin currently diluted by, the need to hire and train auditors. Auditors are people. A business whose growth is gated by human capacity is a professional services business with software attached, not a software business.

Third, the original Alchemy underwriting has not visibly been met. Intertek targeted IFRS EBITDA margins above 30% and IFRS EBIT margins above 25% by year five, which would have been 2023.¹⁰ Corporate Assurance as a whole ran at a 22.6% operating margin in 2025.³ The company does not disclose Alchemy's standalone economics, so this is not proof of a shortfall — but the absence of the disclosure, seven years after paying a software multiple and explicitly promising software margins, is itself informative. Companies generally publish the numbers that vindicate them.

What is fair to say in the company's favour is that it keeps investing in the direction.

Intertek People Assurance has partnered with Synthesia, the UK's largest generative AI media company by valuation, to let clients produce dynamic, multi-lingual, branded training videos at speed and low production cost — a sensible use of generative AI that lowers the marginal cost of the most expensive input in the training product.¹ Assuris launched Digital Product Passport services combining advisory, assurance, data and training to help clients meet circular-economy and traceability regulation, and Intertek added ISO 42001 AI management systems certification.¹ These are real products aimed at real emerging mandates.

The honest verdict, then, is a split one. Corporate Assurance is Intertek's best growth asset and its second-best margin asset, and the switching costs embedded in a client's compliance documentation are among the most durable in the group.

But the specific claim that it justifies a software-style valuation multiple for the whole company is not currently supported by published evidence, and the burden of proof sits with management, not with the skeptic. Which is a fitting place to widen the lens, because Intertek's competitors have been making rather different claims about themselves — and delivering rather different numbers.

↑ Back to Top

VII. Strategic Moats & Competitive Landscape: 7 Powers & 5 Forces in the TIC Oligopoly [20 Minutes]

Imagine a war room with four chairs. On the table are the FY2025 results of the four listed companies that dominate global testing, inspection and certification, and the exercise is to work out which one is winning.

Eurofins Scientific reported revenue of €7,296m, up 5.0% as reported and 4.1% organically, with basic EPS up 24% to €2.31 and an adjusted EBITDA margin of 24.3% on mature-scope revenues.¹⁶ SGS SA posted turnover of CHF 6,945m with organic growth of 5.6%, EPS up 12.3%, nineteen bolt-on acquisitions closed representing more than CHF 190m of annual sales, and guidance for 5% to 7% organic sales growth in 2026.¹⁴ Bureau Veritas delivered revenue of €6,466.4m with organic growth of 6.5%, crossed €1bn of adjusted operating profit for the first time at €1,053m, expanded its adjusted operating margin 32 basis points to 16.3%, generated €824.2m of free cash flow at 107% cash conversion, and announced a new €200m buyback.¹⁵ And Intertek, on £3,431.6m of revenue, delivered a like-for-like revenue increase of 3.9% at constant currency and an 18.1% adjusted operating margin.³

Read those four lines together and one pattern jumps out. Intertek had the highest operating margin in the peer group by a wide margin — nearly two full percentage points above Bureau Veritas — and the lowest organic growth rate. Bureau Veritas grew organically at 6.5% against Intertek's 3.9%. SGS grew at 5.6%. Even Eurofins, whose 4.1% organic growth was described in its own release as below secular averages, out-grew Intertek.^1514163

This is the single most important competitive fact in the story, and it deserves to be stated without spin. Intertek is roughly half the size of its three listed peers and is the most profitable of them, which is an unambiguous testament to portfolio quality and operational discipline.

But in the most recent complete year it was also the slowest-growing, in an industry which EQT itself characterises as growing at mid-to-high single digits over the medium term.² A company earning premium margins while under-growing its market is either harvesting a superior portfolio or under-investing in its franchise, and the market's judgement on which of those it was is written in the share price at which the bid arrived.

Below the listed four sits a long tail. The German technical inspection houses — TÜV SÜD, TÜV Rheinland — and DEKRA are privately or foundation-controlled, with deep strength in automotive and heavy industrial engineering. UL LLC anchors North American safety standards and is the direct competitive counterpart to the ETL mark. In China, 华测检测 Centre Testing International has built genuine domestic scale, and 中国质量认证中心 China Quality Certification Centre occupies the state-linked certification role.

Independent market research sizes the global TIC services market at approximately US$265.6 billion in 2025, with the five leading providers — Bureau Veritas, DEKRA, Eurofins, Intertek and SGS — collectively holding roughly 11.7% share, and Eurofins the largest at around 3%.¹⁸ That fragmentation is the structural fact underpinning every one of these companies' bolt-on acquisition strategies: there is always another regional laboratory to buy.

Run Hamilton Helmer's 7 Powers over Intertek properly, which means being willing to grade some of them down.

Switching costs are the strongest power and they are real, but they are unevenly distributed. In Corporate Assurance and in retailer-mandated consumer certification they are formidable, for the documentation reasons already discussed. In commodity cargo inspection, where a trader wants a sample drawn at a specific port on a specific day, they are close to nil — which is precisely why Caleb Brett's revenue tracks trade flows rather than contracted volumes.

Cornered resource is the second-strongest, and it is the accreditation and permission stack described earlier, layered onto a network of over 1,000 facilities across more than 100 countries.¹ The honest qualification is that SGS, Bureau Veritas and Eurofins each hold a comparable stack. This power protects the oligopoly against outsiders far more than it protects Intertek against the other three.

Scale economies are genuine but bounded. Fixed capital for specialised equipment — mass spectrometers, anechoic electromagnetic compatibility chambers, HVAC performance chambers of the kind Intertek expanded in Plano, Texas — is spread across large sample volumes in hub laboratories, with satellite sites collecting and routing samples.¹ The bound is geography: you cannot ship a Malaysian mineral sample to Texas economically, which is why Intertek opened a sample preparation facility in Kota Kinabalu.¹ Scale in this industry is regional and repeated, not global and singular.

Branding is legitimate. The ETL mark and the TQA positioning function as trust badges in retailer vendor-approval processes. The related claim of counter-positioning — TQA assurance versus commoditised tick-box testing — does not survive scrutiny, because counter-positioning requires that incumbents be unable to respond without damaging their own business. SGS, Bureau Veritas and Eurofins all market integrated assurance offerings. This is competitive positioning, not counter-positioning, and it should not be scored as a structural power.

Process power sits at moderate. Intertek's productivity metrics — revenue, operating profit and free cash flow per head, which Lacroix cites as evidence of disciplined volume, price and mix management — are the best evidence for it, and the falling staff turnover supports the claim that institutional knowledge is being retained.³⁸ There is no meaningful network economy here (one more customer does not make the service better for the others) and no process of cornered pricing power over suppliers.

Porter's five forces, briefly, in prose. New entrants face a low probability of success, not because capital is scarce but because permission is: the accreditation and recognition stack takes years and cannot be bought outright. Buyer power is moderate and asymmetric — a 400,000-strong client base is fragmented, but Walmart, Target or Amazon negotiating a global vendor testing programme is a very different counterparty from a mid-sized furniture importer.

Supplier power is low, since instrument makers are numerous and the scarce input is accredited human expertise, which the falling turnover rate suggests Intertek manages competently. Substitution is the force most likely to be mis-scored: testing mandated by law is not substitutable, but the audit hour and the document review absolutely are, and generative AI attacks exactly those. Rivalry is moderate and mostly rational, contested on capability and geography rather than price — which is precisely what the peer group's simultaneous margin expansion demonstrates.

The strategic conclusion is uncomfortable and worth holding. Intertek's moat protects the industry's profit pool very effectively and Intertek's share of it adequately. What the moat does not do is generate growth. And a business whose defences are excellent but whose top line trails its peers is a business that eventually attracts people who think they can fix the second problem without breaking the first.

↑ Back to Top

VIII. Capital Allocation, M&A Discipline, & Management Credibility Audit [15 Minutes]

On 10 April 2026, Intertek received an unsolicited proposal from EQT of £51.50 per share in cash. The board rejected it. EQT came back with two further indicative proposals. The board rejected both. On 11 May 2026 EQT submitted a final non-binding offer delivering total value of £61.077 per share, and on 13 May, after evaluating it with its advisers and following what it described as significant engagement with shareholders, the board announced it would be minded to recommend those terms.²

That sequence — three rejections and a nineteen-percent escalation from first bid to last — is the single best piece of evidence about this board's conduct, and it deserves credit before the criticism starts. Boards that fold at first contact destroy value silently. This one did not.

The context makes it more interesting.

Four days after EQT's opening approach, on 14 April 2026, Intertek announced a strategic review to evaluate the potential separation, by sale or demerger, of Intertek Energy & Infrastructure — World of Energy plus Industry and Infrastructure, £1.6bn of 2025 revenue — from Intertek Testing & Assurance, comprising Consumer Products, Corporate Assurance and Health and Safety, at £1.9bn.⁷ The stated rationale was that two specialist businesses could accelerate growth through a focused portfolio strategy, sharper capital allocation and faster in-market execution, with implementation targeted by the middle of 2027.⁷ The same announcement reported a strong Q1 2026 with like-for-like revenue growth of 5.4% at constant currency.⁷ When the board granted EQT confirmatory diligence in May, it paused further work on the strategic review.²

Read in sequence, the review reads less like a coincidence and more like a response: a board that had just been told by a private equity firm that its assets were worth far more separately than together, announcing four days later that it was exploring exactly that.

The board's own evaluation language is candid about the trade-off it ultimately made, stating that while it remained highly confident in the standalone strategy and the value creation opportunity from the review, the acquisition offered shareholders certain and immediate cash.² That is a board choosing certainty over conviction — a defensible choice, and a revealing one.

The capital allocation framework the company operated in the meantime was explicit and, unusually, actually followed.

First priority, organic growth, with capex targeted at 4–5% of revenue: £145m invested in 2025, up 7%, with £150–160m guided for 2026.³⁵ Second, a progressive dividend targeting roughly a 65% payout ratio: 165.0p for 2025, up 5.4%, costing £260.3m and covered 1.5 times by adjusted earnings.³ Third, acquisitions in high-growth, high-margin ATIC segments: four deals in 2025 for £157m total consideration.³ Fourth, leverage held within 1.3–1.8x net debt to EBITDA, with optionality to return excess capital when it cannot be deployed at attractive returns.³

The evidence that this was more than a slide is in the behaviour at the boundaries. In FY2024, with leverage at 0.7x — far below the target range — the company raised the dividend 40.1% to rebase toward the 65% payout policy and announced an initial £350m buyback.⁶ That buyback was completed in 2025, taking total shareholder returns for the year to £602m and leverage to 1.3x.³ Then, at the FY2025 results, with leverage at the bottom of the range, no new buyback was announced.

Pressed on this by Morgan Stanley's Annelies Vermeulen, Lacroix explained that at 1.3x the company preferred to keep firepower for an improving M&A pipeline, and committed that if leverage ended 2026 below the minimum threshold the board would reconsider returning excess cash.⁸ Leverage stood at 1.4x at 30 June 2026, with a weighted average interest rate of 3.9% and undrawn committed headroom of £172.5m against £345.5m at the end of 2025.¹ The framework was applied consistently in both directions, which is the test.

A note on alignment, since the offer document forces an unusually precise disclosure of it.

The irrevocable undertakings appendix reveals that Lacroix held 616,664 Intertek shares at the latest practicable date, roughly 0.40% of issued capital — a meaningful personal stake worth well over £35m at the offer price, and the kind of holding that makes a chief executive economically indifferent between a good outcome for shareholders and a good outcome for himself.² The contrast with the newer arrivals is stark: Steven Mogford held 277 shares and Laura Crespi none.² That is not a criticism of either — both had been in their roles for weeks — but it is the reason the board's independence in negotiating the price rested substantially on directors whose own economics were only lightly engaged, with PJT Partners brought in specifically to provide independent Rule 3 advice.² Investors assessing any recommended scheme should look at who around the table actually had money in the outcome.

The returns are the strongest number in the file.

ROIC of 21.3% in 2025 against 22.4% in 2024, with organic ROIC — which excludes acquisitions in their first twelve months — improving to 23.0% from 22.5%, and a three-year average ROIC of 21.4%.³⁵ Acquisitions completed between 2023 and 2025 contributed £35.5m of revenue in FY2025 at a 34% adjusted operating profit margin, well above the group's 18.1%.²³ The decline in headline ROIC while organic ROIC rose is exactly the signature you would expect from a disciplined acquirer: recent deals dilute the ratio while they integrate, and the underlying business keeps improving.

Now the stress test, because a skeptical investor would have three specific arguments and only one of them is easily answered.

The easy one is goodwill. Group goodwill stood at £1,422.3m at 31 December 2025, up from £1,365.9m, tested annually with no impairments recognised.³ Against £620m of annual adjusted operating profit and leverage of 1.3x, that is not balance sheet bloat, and it is well below the figure sometimes cited. The Swiss defined benefit scheme showed a £3.9m deficit on an IAS 19 basis at end-2025; the UK scheme, closed to new entrants in 2002 but open to future accrual, is fully funded.² There is no hidden liability story here.

The harder argument is about adjusted earnings.

Intertek's headline 18.1% margin is an adjusted figure; the statutory operating margin for 2025 was 15.8%, unchanged from 2024, and statutory profit after tax actually fell 1.1% to £363.2m while adjusted diluted EPS rose 5.4%.³ The gap is separately disclosed items: £35.9m of acquisition intangible amortisation, £4.3m of acquisition and integration costs, and £37.1m of restructuring costs, the last of which more than doubled from £15.8m in 2024.³ Those restructuring costs belong to a cost reduction programme that started in 2022 and is expected to last up to five years, with the associated charges excluded from adjusted operating profit on the basis that they are not expected to recur.³ A programme running for five consecutive years, whose charges grow rather than shrink, sits awkwardly with the word "non-recurring."

Analysts pressed exactly this point. RBC's Karl Green asked Lacroix to reconcile £37m of charges against the £8m of 2026 cost savings management had quantified — an almost five-to-one ratio — and asked what P&L restructuring charges to expect in 2026.

Lacroix confirmed the £8m figure was the total expected cost-base saving, declined to guide on future restructuring charges, said each case was assessed individually with clear booking rules and full audit review, and noted that 2026 is the final year of the five-year programme.⁸ Earlier, answering UBS's Rory McKenzie, he had been more revealing about what the money bought: cost reduction in Transportation Technologies and Chemicals & Pharma, streamlining of overheads and management layers, and exiting a few sites where after two and a half years the results "were not compelling and they were starting to destroy value."⁸

That is a fair and even admirable answer — a chief executive naming underperforming units and acting on them. But it also concedes the analytical point. A charge that closes a value-destroying site is a real economic cost of a prior capital allocation error, and excluding a five-year run of such costs from the earnings metric on which incentives and valuation are based flatters the record.

An investor should track both the adjusted and statutory series, and note that the 240 basis points of margin accretion delivered since 2023 looks considerably less dramatic on a statutory basis. A related judgement appeared in H1 2026, where the consolidated effective tax rate of 40.0% diverged sharply from the 26.0% adjusted rate, predominantly because of tax costs relating to previous periods treated as a separately disclosed item.¹

The third argument is the one the bid answers. If Consumer Products and Corporate Assurance generate two-thirds of group profit and grow fastest, and World of Energy earns single-digit margins on a fifth of revenue, why were they in the same company at all? Management's answer for years was cross-selling and shared infrastructure.

The board's April 2026 announcement conceded that two specialist businesses might allocate capital more sharply.⁷ EQT's answer is more direct still: its stated intention is to conduct a strategic evaluation that will consider opportunities to optimise the portfolio, including strategic acquisitions, partnerships and divestitures, and evaluate the appropriate corporate structure going forward.² The conglomerate discount was real, everybody eventually agreed it was real, and a private owner is going to be paid for closing it.

Which brings the whole question into focus: what exactly is being bought, and what has to go right.

↑ Back to Top

IX. Strategic Position, Bull vs. Bear Investment Spine, & Risk Radar [15 Minutes]

Strip away the advisers — Goldman Sachs, J.P. Morgan Cazenove and PJT Partners for Intertek, the last providing the independent Rule 3 advice; Morgan Stanley, Barclays and Deutsche Bank for Bidco — and the transaction poses a clean question.²

EQT is paying approximately £10.9 billion of enterprise value, a 62% premium to the undisturbed price of £37.70 and still a 19% premium to the 52-week high of £51.30, for a business that grew like-for-like revenue 3.9% last year.²³ Either the public market was mispricing a compounder, or EQT believes it can materially change the growth rate. Both parties cannot be right.

EQT's thesis is on the record.

It argues the global ATIC industry will grow at mid-to-high single digits over the medium term; that increased investment and renewed strategic focus on innovation underpinned by greater AI adoption can accelerate Intertek's growth; that its dedicated Digital & AI team will support commercial excellence, innovation, technology-enabled service delivery and AI adoption; and that it will bring sourcing and execution capability to accelerate M&A.² It cites thirty years of services investing, US$40.4 billion of equity deployed across 56 services companies, and its 2024 take-private of Dechra Pharmaceuticals, where it says it tripled R&D investment relative to Dechra's last full year as a public company and funded an ambitious M&A agenda.² It also states that the additional flexibility of a private environment will let it focus on sustainable long-term value.²

Translated: EQT thinks Intertek was under-investing because public-market margin discipline made under-investment the path of least resistance. That is a coherent critique of a company that hit a raised margin target while growing slower than every listed peer.

Why the business wins from here. The regulatory direction of travel is genuinely favourable and increasingly specific. Digital Product Passport requirements, circular-economy compliance, EU deforestation rules covering wood, rubber, cocoa, coffee, cattle, soy and palm oil, ISO 42001 for AI management systems, sustainability data verification — each converts a policy sentence into a recurring, auditable obligation that somebody independent must sign.¹⁴ Intertek is positioned to sell into all of them.

The operating machine is demonstrably improving: H1 2026 delivered what management describes as the eleventh consecutive six-month period of mid-single-digit like-for-like revenue growth and the seventh consecutive period of double-digit adjusted EPS growth at constant currency, with cash conversion of 116%, free cash flow up £82.5m to £138.5m, and margin up 100 basis points to 17.5%.¹ And the cash generation is real rather than accounting: £2.3bn of cumulative operating cash flow across three years funded £600m of investment and £985m of shareholder returns without equity dilution.²³

Why it may not. Three things could break the case.

The first is that the growth gap is structural rather than cyclical. Intertek's answer to slower growth has been baseline effects — Lacroix walked analysts carefully through World of Energy's 8.7% like-for-like growth in 2023 and 8.0% in 2024 to explain the 2025 decline, and noted that group like-for-like growth excluding World of Energy was 4.7% in November and December against a reported exit rate of 1.9%.⁸ The explanation is arithmetically fair.

But it has now been offered for two consecutive years about the same division, and a company that needs to exclude a fifth of its revenue to describe its growth rate has a portfolio problem, not a comparison problem. Bureau Veritas grew 6.5% organically in the same period without such adjustments.¹⁵

The second is technology. This is the risk most likely to be underestimated, and the mechanism deserves plain language. Intertek's physical testing — putting a garment in a machine, running a mass spectrometer over a fuel sample — is essentially un-automatable by software, because someone still has to obtain and destroy the sample.

But a meaningful share of group revenue is not physical testing at all. It is audit hours, document review, regulatory research and report writing. Those activities are billed by the hour and consist largely of reading documents and comparing them to rules, which is exactly the task at which large language models have become competent.

Lacroix's response, on the results call, was notably two-sided: he described AI as an offensive opportunity through the Intertek AI² independent AI assurance programme, and as an internal productivity tool applied to test and audit report quality review, auditor and inspector scheduling, lead qualification, contract review using Harvey, and global market access protocols.¹⁸ Both framings can be true and still leave a revenue problem, because productivity gains in an hours-billed business flow to the customer unless the pricing model changes.

Whether Intertek can convert audit automation into higher-margin subscription revenue rather than lower billable hours is the most important unresolved question in the business, and no current disclosure answers it.

The third is geopolitics feeding directly into the divisions that can least absorb it.

The H1 2026 World of Energy margin decline was attributed in part to the war in the Gulf affecting Caleb Brett, with reduced imports from the Middle East into Asia and temporary business disruption also hitting Industry Services in the region.¹ On tariffs, Lacroix reported that the prevailing client posture was wait-and-see — that supply chain changes are costly, risky and slow, and clients will only re-engineer if the economics hold for many years — while noting that recent developments were incrementally better for China and India.⁸ That is a credible read, and it cuts both ways: deferred supply-chain decisions defer the SupplyTek re-engineering revenue Intertek hopes to earn from them.

Meanwhile the automotive R&D retrenchment behind Transportation Technologies' decline reflects Western OEMs losing share in China and absorbing tariff costs in North America, which Lacroix expects to recover progressively from the second half of 2026 — a forecast that is, as of now, unproven.⁸

And there is a fourth risk specific to this moment: the transaction itself. The financial terms are final and will not be increased except in narrowly defined circumstances such as a competing offer.² The scheme requires approval by a majority in number of scheme shareholders present and voting at the court meeting, representing at least 75% in value of shares voted, plus a special resolution passed by 75% of votes cast at the general meeting, plus court sanction.² The board and directors have irrevocably undertaken to vote their own 642,951 shares, approximately 0.42% of issued capital, in favour.²

The offer terms have already reached into the income statement in a way income-oriented holders will have noticed.

Because any dividend paid other than the FY25 final would reduce the cash consideration one-for-one, the board is not proposing an interim dividend for H1 2026 — the first interruption to a progressive payout that had grown at an average of 17% a year over the preceding three years.¹³¹⁷ The economics are neutral, since shareholders receive the value in the consideration instead, but the mechanic is a useful illustration of how completely a recommended scheme freezes a company's normal capital allocation machinery while it runs.

Shares traded around 5,835 pence in early August 2026, a modest discount to the £60.00 cash consideration — the market pricing a high probability of completion, but not certainty, with regulatory conditions and a Q4 2026 to Q1 2027 timetable still to run.¹⁹

The KPIs that matter. Three, and only three, are worth tracking.

Like-for-like revenue growth at constant currency is the first and most important, because it is the metric on which the entire debate turns. Guidance is mid-single digit annually across the cycle; the record is 6.3% in FY2024, 3.9% in FY2025, 5.4% in Q1 2026 and 4.9% in H1 2026.¹³⁶⁷ The right test is not whether the number is mid-single digit but whether it is mid-single digit including World of Energy and without baseline explanations.

Adjusted operating margin progression toward the 18.5%+ medium-term target is the second, watched alongside the statutory margin. The adjusted figure was 18.1% for FY2025 and 17.5% in H1 2026, up 100 basis points.¹³ The gap between adjusted and statutory is where the quality of that progression is revealed.

ROIC together with cash conversion is the third, because it is the only pair that catches a serial acquirer drifting. Cash conversion was 110% in FY2025 and 116% in H1 2026; ROIC was 21.3% with organic ROIC at 23.0%.¹³ If organic ROIC declines while headline ROIC holds up, the acquisitions are carrying the story.

One structural caveat overrides all three. If the scheme becomes effective, this disclosure regime ends. The non-executive directors will resign on completion, Bidco expects headcount reductions in public-company and back-office functions no longer required, and the reporting obligations that produce these KPIs disappear.² For public-market investors, the tracking question resolves into a much simpler one about deal completion — and the analytical interest shifts to what the private owner does with the assets, which will only become visible again if and when parts of Intertek return to public markets.

↑ Back to Top

X. Playbook: Key Business & Investing Lessons [10 Minutes]

Lesson 1: The regulatory tollbooth is the most durable revenue model in services — but it is a toll on activity, not on existence. Intertek's demand is created by law, retailer mandate and insurer requirement rather than by discretionary customer preference, which is why the business survived a century of upheaval and compounded through recessions. What the 2025 numbers show is the limit of that logic. A tollbooth earns nothing when traffic stops.

Caleb Brett's revenue depends on cargoes actually moving through Middle Eastern ports; Transportation Technologies depends on OEMs actually funding R&D projects. Mandated demand is resilient demand, not growing demand. Investors should ask, for each revenue line, whether the mandate attaches to a stock (every facility must be certified annually) or a flow (every shipment must be inspected), because the first is an annuity and the second is a cyclical.

Lesson 2: Buying a software multiple does not buy software economics — and the disclosure will tell you which one you got. Intertek paid roughly 22 times billings EBITDA for Alchemy and 15 times EBITDA for SAI Global Assurance, in both cases telling shareholders upfront that returns would exceed the cost of capital only in year five.¹⁰¹¹ The strategic reasoning was sound: embed workflow software in a client's compliance process and you convert a transactional relationship into a contractual one.

The execution question is whether the acquired business retains software gross margins and software growth once it sits inside a services organisation whose selling motion, incentive structure and delivery model are built around billable expertise. Seven years on, Intertek publishes no ARR, no subscription revenue and no retention metric, and the host division's margin fell last year.³ The general rule for investors: when a company pays a technology multiple for a technology asset, it acquires an obligation to report technology metrics. Silence is a data point.

Lesson 3: Hub-and-spoke density is the real capital-efficiency engine, and its limits are geographic. Intertek's returns come from concentrating expensive instruments in hub laboratories while satellite offices collect, prepare and route samples — which is why sample-preparation facilities in Kota Kinabalu and laboratory expansions in Plano and Bentonville matter more to ROIC than any strategy slide.¹⁴ Two implications follow.

First, network density in a region compounds: each additional collection point raises utilisation of an already-paid-for hub, which is why the same 4–5% of revenue in capex produced ROIC above 21% rather than the low-teens returns typical of asset-heavy services.³ Second, the strategy caps out at the point where sample logistics become uneconomic, which is why this industry consolidates region by region and why there is always another local laboratory worth acquiring.

Lesson 4: In fragmented, trust-based industries, patient bolt-on acquisition beats the transformational deal — and the sourcing channel is the edge. Intertek's best returns came not from its largest deals but from a steady programme of small ones: four in 2025 for £157m combined, with deals completed between 2023 and 2025 running at a 34% operating margin against the group's 18.1%.²³ The mechanism Lacroix described matters more than the arithmetic: cultivating bilateral relationships with founder-owners over years, so that when the owner is ready to sell, there is no auction.⁸ Compare that with Moody, bought at scale from a private equity seller immediately before its end-market cycle turned.

The larger the deal, the more likely it is sourced from a process, priced by a competitor's bid, and timed by the seller rather than the buyer.

Lesson 5, and the one this whole story is really about: quality and growth are separable, and public markets pay for the combination. Intertek in 2025 was a demonstrably excellent business — the highest margins in its peer group, 21% returns on capital, 110% cash conversion, a management team that set targets, hit them early, and raised them.³ It was also the slowest-growing of the four listed majors, carrying a fifth of its revenue in a single-digit-margin division, with a conglomerate structure that everyone eventually agreed was suppressing value.⁷¹⁵ The market's response was a valuation that a private equity firm could beat by 62% while still expecting to make money — by separating what should never have been combined and funding growth the public equity story had been discouraging.² The uncomfortable lesson for long-term investors is not that the market was wrong.

It is that operational excellence and disciplined capital allocation, delivered consistently for a decade, were not sufficient. Portfolio construction — deciding which businesses belong together at all — turned out to be the decision that determined who captured the value. And it is a decision that boards defer far more easily than they defer any other.

References

1. 2026 Half Year Results Announcement — Intertek Group plc, 2026-07-31 ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

2. Recommended Final Cash Acquisition of Intertek Group plc by Isotope Bidco Limited (Rule 2.7 Announcement) — Intertek Group plc / EQT, 2026-06-18 ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

3. 2025 Full Year Results Announcement — Intertek Group plc, 2026-03-03 ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

4. Our History — Intertek Group plc ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

5. 2025 Full Year Results Audiocast Script — Intertek Group plc, 2026-03-03 ↩↩↩

6. 2024 Full Year Results Announcement — Intertek Group plc, 2025-03-04 ↩↩↩

7. Strategic Review Initiation & Trading Statement — Intertek Group plc, 2026-04-14 ↩↩↩↩↩↩↩

8. Intertek Group Q4 Earnings Call — Yahoo Finance, 2026-03-03 ↩↩↩↩↩↩↩↩↩↩↩↩↩

9. Intertek to Acquire Leading Technical Services Group Moody International — Intertek Group plc, 2011-03-07 ↩↩↩

10. Intertek Expands its Global Assurance Business with the Acquisition of Alchemy — Investor Presentation, Intertek Group plc, 2018-08-03 ↩↩↩↩↩↩

11. Intertek to Acquire SAI Global Assurance — Intertek Group plc, 2021-05-13 ↩↩↩↩↩

12. Executive Management — Intertek Group plc ↩↩

13. Intertek promotes Laura Crespi to CFO as Colm Deasy moves to Vietnam — AJ Bell, 2026-03-26 ↩↩↩

14. SGS 2025 Full Year Results — IIOA, 2026-02 ↩↩

15. Sector-leading organic revenue growth of 6.5% in FY 2025; strong margin improvement to 16.3% — Bureau Veritas, 2026-02-25 ↩↩↩↩

16. Eurofins Delivers FY 2025 Objectives with a 24% EPS Growth — Eurofins Scientific, 2026-01-29 ↩↩

17. Intertek clocks double-digit profit growth, skips dividend ahead of EQT deal — Investing.com, 2026-07-31 ↩

18. Testing, Inspection and Certification (TIC) Market Analysis — Global Market Insights ↩

19. Intertek Group plc (ITRK) Company Page — London Stock Exchange ↩